Zai Lab (NASDAQ:ZLAB) PT Set at $46.00 by Leerink Swann
Leerink Swann set a $46.00 price target on Zai Lab (NASDAQ:ZLAB) in a research report report published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the stock.
Several other equities analysts also recently weighed in on the company. BidaskClub raised Zai Lab from a sell rating to a hold rating in a research report on Wednesday, June 5th. Zacks Investment Research raised Zai Lab from a hold rating to a buy rating and set a $30.00 target price for the company in a research report on Saturday, May 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Zai Lab has an average rating of Buy and an average price target of $36.90.
NASDAQ ZLAB opened at $29.71 on Tuesday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -11.25 and a beta of 0.96. Zai Lab has a 1-year low of $14.29 and a 1-year high of $33.86.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Article: QQQ ETF
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.